Effects of transoral gastroplasty on glucose homeostasis in obese subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 5, 2013, Pages 1901-1910

  Leccesi, Laura ^a   Panunzi, Simona ^c   De Gaetano, Andrea ^c   Familiari, Pietro ^b   Iaconelli, Amerigo ^a   Guidone, Caterina ^a   Mazzarella, Ada ^a   Costamagna, Guido ^b   Mingrone, Geltrude ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FAT FREE MASS; FEMALE; FOLLOW UP; GASTROPLASTY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSORAL GASTROPLASTY; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION;

ADOLESCENT; ADULT; BODY MASS INDEX; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GASTRIC INHIBITORY POLYPEPTIDE; GASTROPLASTY; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; OBESITY; OBESITY, MORBID; PREDIABETIC STATE; PROSPECTIVE STUDIES; RISK; ROME; WEIGHT LOSS; YOUNG ADULT;

EID: 84877716490     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3857     Document Type: Article

References (37)

1. Drenick EJ, Bale GS, Seltzer F, Johnson DG. Excessive mortality and causes of death in morbidly obese men. JAMA. 1980;243:443-445.
2. Hofsø D, Jenssen T, Hager H, Røislien J, Hjelmesaeth J. Fasting plasma glucose in the screening for type 2 diabetes in morbidly obese subjects. Obes Surg. 2010;20:302-307.
3. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
4. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
5. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet Med. 2007;24: 451-463.
6. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991;115: 956-961.
7. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316-323.
8. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567-1576.
9. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577-1585.
10. Kantsevoy SV, Hu B, Jagannath SB, et al. Technical feasibility of endoscopic gastric reduction: a pilot study in a porcine model. Gastrointest Endosc. 2007;65:510-513.
11. Moreno C, Closset J, Dugardeyn S, et al. Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: results of the second human pilot study. Endoscopy. 2008; 40:406-413.
12. ASGE Technology Committee, Kethu SR, Banerjee S, Barth BA, et al. Endoluminal bariatric techniques. Gastrointest Endosc. 2012; 76:1-7.
13. Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulinresistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975-980.
14. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, De-Fronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006; 55:1430-1435.
15. Hills SA, Balkau B, Coppack SW, et al. The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk). I. Methodology and objectives. Diabetologia. 2004;47:566-570.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
17. Mattews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RL. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
18. Rojo-Martínez G, Esteva I, de Adana SR, et al. Patterns of insulin resistance in the general population of southeast Spain. Diabetes Res Clin Pract. 2004;65:247-256.
19. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470.
20. DallaMan C, Caumo A, Cobelli C. The oral glucose minimal model: estimation of insulin sensitivity from a meal test. IEEE Trans Biomed Eng. 2002;49:419-429.
21. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298.
22. Mosteller RD. Simplified calculation of body surface area. N Engl J Med. 1987;317:1098.
23. Tripathy D, Almgren P, Toumi T, Groop L. Contribution of insulinstimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care. 2004;27: 2204-2210.
24. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebocontrolled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM Study. Obesity. 2012;20:1426-1436.
25. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248-256.
26. Williams R, Van Gaal L, Lucioni C. CODE-2 Advisory Board 2002 Assessing the impact of complications on the costs of type II diabetes. Diabetologia. 45:S13-S17.
27. Tuomilehto J. Nonpharmacologic therapy and exercise in the prevention of type 2 diabetes. Diabetes Care. 2009;32:S189-S193.
28. DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care. 2011;34: S202-S209.
29. Pontiroli AE, Folli F, Paganelli M, et al. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study. Diabetes Care. 2005;28:2703-2709.
30. Pontiroli AE, Pizzocri P, Librenti MC, et al. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab. 2002;87:3555-3561.
31. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623-1630.
32. Thaler JP, Cummings DE. Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150:2518-2525.
33. Parlevliet ET, de Leeuw van Weenen JE, Romijn JA, Pijl H. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2010;299:E318-E324.
34. Ahrén B, Pacini G. Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. Am J Physiol Endocrinol Metab. 1999;277:E996-E1004.
35. Tesauro M, Schinzari F, Adamo A, et al. Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care. 2013;36:683-689.
36. McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab. 2007; 293:E1746-E1755.
37. Gault VA, Irwin N, Green BD, et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes. 2005;54:2436-2446.